Overview

Study to Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Status:
Recruiting
Trial end date:
2025-09-30
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
Phase:
Phase 1
Details
Lead Sponsor:
SystImmune Inc.